Giselle Santos Magalhães
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Giselle Santos Magalhães has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Maria José Campagnole-Santos
Department of Physiology and Biophysics and INCT-Nanobiopharmaceutics, ICB, Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, Brazil
9 shared publications - Maria da Glória Rodrigues-Machado
Faculdade de Ciências Médicas de Minas Gerais
7 shared publications - Robson Augusto Souza Santos
Federal University of Minas Gerais
6 shared publications - Daisy Motta-Santos
Department of Human Movement Sciences (DCMH), State University of Minas Gerais (UEMG), Ibirité, MG, Brazil
4 shared publications - Luciola Silva Barcelos
Department of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte 31270-901, MG, Brazil
4 shared publications Maria Jose Campagnole-Santos
Department of Physiology and Biophysics, , , , Belo Horizonte, Brazil
3 shared publications
Latest Publications
- Open Access
- 18 June 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1540475
Oral Angiotensin-(1-7) formulation after established elastase-induced emphysema suppresses inflammation and restores lung architecture
Background: Chronic obstructive pulmonary disease (COPD), a prevalent age-related condition, ranks among the leading causes of global mortality. It is characterized by chronic inflammation, cellular senescence, and irreversible lung tissue damage, with no curative treatments currently available. Angiotensin-(1-7) [Ang-(1-7)] has demonstrated anti-inflammatory and regenerative potential in preclinical models. This study aimed to investigate the therapeutic effects of oral Ang-(1-7) on senescence, inflammation, and tissue regeneration in a model of elastase-induced pulmonary emphysema.Methods: Male C57BL/6 mice were subjected to emphysema induction through three intratracheal instillations of porcine pancreatic elastase (PPE). One week after the final elastase instillation, the mice were treated with Ang-(1-7) encapsulated in hydroxypropyl-β-cyclodextrin to enhance its bioavailability. The treatment was administered daily for 4 weeks. Histological assessments, gene expression analysis, and protein quantification through Western blot were performed to evaluate lung architecture, inflammation, and senescence markers.Results: The results showed that elastase exposure led to significant lung damage, including enlarged airspaces, increased collagen deposition and upregulated expression of collagen I/III and MMP9. Markers of inflammation and senescence were significantly elevated in the untreated emphysema group. However, treatment with Ang-(1-7) reversed these changes, reducing collagen deposition, restoring alveolar structure, and suppressing inflammation and senescence. Additionally, Ang-(1-7) modulated key signaling pathways, reactivating the Wnt/β-catenin pathway for tissue regeneration and inhibiting NF-κB activation, critical for inflammation suppression.Conclusion: These findings suggest that Ang-(1-7), when administered after disease establishment, demonstrates potential to reverse structural lung damage and suppress chronic inflammation in experimental models, indicating a promising direction for future translational and clinical research in COPD.
- 18 June 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1540475
Open AccessOral Angiotensin-(1-7) formulation after established elastase-induced emphysema suppresses inflammation and restores lung architecture
Background: Chronic obstructive pulmonary disease (COPD), a prevalent age-related condition, ranks among the leading causes of global mortality. It is characterized by chronic inflammation, cellular senescence, and irreversible lung tissue damage, with no curative treatments currently available. Angiotensin-(1-7) [Ang-(1-7)] has demonstrated anti-inflammatory and regenerative potential in preclinical models. This study aimed to investigate the therapeutic effects of oral Ang-(1-7) on senescence, inflammation, and tissue regeneration in a model of elastase-induced pulmonary emphysema.Methods: Male C57BL/6 mice were subjected to emphysema induction through three intratracheal instillations of porcine pancreatic elastase (PPE). One week after the final elastase instillation, the mice were treated with Ang-(1-7) encapsulated in hydroxypropyl-β-cyclodextrin to enhance its bioavailability. The treatment was administered daily for 4 weeks. Histological assessments, gene expression analysis, and protein quantification through Western blot were performed to evaluate lung architecture, inflammation, and senescence markers.Results: The results showed that elastase exposure led to significant lung damage, including enlarged airspaces, increased collagen deposition and upregulated expression of collagen I/III and MMP9. Markers of inflammation and senescence were significantly elevated in the untreated emphysema group. However, treatment with Ang-(1-7) reversed these changes, reducing collagen deposition, restoring alveolar structure, and suppressing inflammation and senescence. Additionally, Ang-(1-7) modulated key signaling pathways, reactivating the Wnt/β-catenin pathway for tissue regeneration and inhibiting NF-κB activation, critical for inflammation suppression.Conclusion: These findings suggest that Ang-(1-7), when administered after disease establishment, demonstrates potential to reverse structural lung damage and suppress chronic inflammation in experimental models, indicating a promising direction for future translational and clinical research in COPD.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA1730
Reduction of anxious and aversive behavior to allergen in mice with allergic lung inflammation and treated with angiotensin-(1-7).
Background: Mechanisms of allergic lung inflammation are well widely studied but little is known about its influences on brain activity, and behavior. The Angiotensin-(1-7) [Ang-(1-7)] / Mas receptor axis is associated with attenuation of airway inflammation, pulmonary remodeling and bronchial hyperresponsiveness in an experimental model of asthma. Aims: In this study, we assessed a possible change in the behavior induced by allergic lung inflammation. Furthermore, we asked if the treatment with Ang-(1-7) could reverse this behavior change. Methods: Mice were assigned to three groups: Control, OVA and OVA+Ang-(1-7). In the OVA groups, mice were sensitized to ovalbumin (OVA; 20 μg, i.p., four times, 14 days apart) and challenged three times per week (1% by nebulized, days 21-46). After 35 days, mice were treated with Ang-(1-7) (days 35-48). An adapted classic passive avoidance test was performed, using an OVA aerosol as an aversive stimulus, in addition, to the Elevated Plus Maze (EPM) test. Results: Allergic mice avoided entering the aversive compartment of the apparatus that had been previously associated with nebulization of the allergen. At the same time, the control, and OVA+Ang-(1-7) groups still moved into the aversive side of the test box. Furthermore, OVA+Ang-(1-7) group showed an increase in the percentage of time and entries in the open arms of the EPM. The treatment with Ang-(1-7) attenuated pulmonary remodeling and decreased IgE levels. Conclusion: The activation of Ang-(1-7)/Mas receptor signaling could be further investigated as an additional strategy for treating asthma-related anxiety.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA1730
Reduction of anxious and aversive behavior to allergen in mice with allergic lung inflammation and treated with angiotensin-(1-7).
Background: Mechanisms of allergic lung inflammation are well widely studied but little is known about its influences on brain activity, and behavior. The Angiotensin-(1-7) [Ang-(1-7)] / Mas receptor axis is associated with attenuation of airway inflammation, pulmonary remodeling and bronchial hyperresponsiveness in an experimental model of asthma. Aims: In this study, we assessed a possible change in the behavior induced by allergic lung inflammation. Furthermore, we asked if the treatment with Ang-(1-7) could reverse this behavior change. Methods: Mice were assigned to three groups: Control, OVA and OVA+Ang-(1-7). In the OVA groups, mice were sensitized to ovalbumin (OVA; 20 μg, i.p., four times, 14 days apart) and challenged three times per week (1% by nebulized, days 21-46). After 35 days, mice were treated with Ang-(1-7) (days 35-48). An adapted classic passive avoidance test was performed, using an OVA aerosol as an aversive stimulus, in addition, to the Elevated Plus Maze (EPM) test. Results: Allergic mice avoided entering the aversive compartment of the apparatus that had been previously associated with nebulization of the allergen. At the same time, the control, and OVA+Ang-(1-7) groups still moved into the aversive side of the test box. Furthermore, OVA+Ang-(1-7) group showed an increase in the percentage of time and entries in the open arms of the EPM. The treatment with Ang-(1-7) attenuated pulmonary remodeling and decreased IgE levels. Conclusion: The activation of Ang-(1-7)/Mas receptor signaling could be further investigated as an additional strategy for treating asthma-related anxiety.
- 7 July 2021
- Published by Wiley in British Journal of Pharmacology
- Vol. 178 (22) , 4428-4439
Asthma: role of the angiotensin‐(1‐7)/Mas (MAS1) pathway in pathophysiology and therapy
The incidence of asthma is a global health problem and requires studies aimed for the development of new treatments to improve its clinical management, reducing personal and economic burdens on the health system. Therefore, the discovery of mediators that promote anti‐inflammatory and pro‐resolutive effects are highly desirable to improve lung function and quality of life of asthmatic patients. In that regard, experimental studies have shown that the angiotensin‐(1‐7)/Mas receptor (MAS1) of the renin‐angiotensin system is a potential candidate for the treatment of asthma. Therefore, we have reviewed findings related to the function of the angiotensin‐(1‐7)/Mas pathway in regulating the processes associated with inflammation, including leukocyte influx, fibrogenesis, pulmonary dysfunction and the resolution of inflammation in asthma. Thus, a knowledge of the role of the angiotensin‐(1‐7)/Mas can help pave the way for the development of new treatments for this disease, which has high morbidity and mortality, through new types of experiments and clinical trials.
- 7 July 2021
- Published by Wiley in British Journal of Pharmacology
- Vol. 178 (22) , 4428-4439
Asthma: role of the angiotensin‐(1‐7)/Mas (MAS1) pathway in pathophysiology and therapy
The incidence of asthma is a global health problem and requires studies aimed for the development of new treatments to improve its clinical management, reducing personal and economic burdens on the health system. Therefore, the discovery of mediators that promote anti‐inflammatory and pro‐resolutive effects are highly desirable to improve lung function and quality of life of asthmatic patients. In that regard, experimental studies have shown that the angiotensin‐(1‐7)/Mas receptor (MAS1) of the renin‐angiotensin system is a potential candidate for the treatment of asthma. Therefore, we have reviewed findings related to the function of the angiotensin‐(1‐7)/Mas pathway in regulating the processes associated with inflammation, including leukocyte influx, fibrogenesis, pulmonary dysfunction and the resolution of inflammation in asthma. Thus, a knowledge of the role of the angiotensin‐(1‐7)/Mas can help pave the way for the development of new treatments for this disease, which has high morbidity and mortality, through new types of experiments and clinical trials.
- Open Access
Predictors and reference equations for augmentation index, an arterial stiffness marker, in healthy children and adolescents
To investigate predictors and propose reference equations for the augmentation index normalized to 75 bpm heart rate (AIx@75) in healthy children and adolescents.This was a cross-sectional, observational study involving 134 healthy children and adolescents ...
Open AccessPredictors and reference equations for augmentation index, an arterial stiffness marker, in healthy children and adolescents
To investigate predictors and propose reference equations for the augmentation index normalized to 75 bpm heart rate (AIx@75) in healthy children and adolescents.This was a cross-sectional, observational study involving 134 healthy children and adolescents ...
- Open Access
- 19 June 2020
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 11, 730
Activation of Ang-(1-7)/Mas Receptor Is a Possible Strategy to Treat Coronavirus (SARS-CoV-2) Infection
Activation of Ang-(1-7)/Mas Receptor Is a Possible Strategy to Treat Coronavirus (SARS-CoV-2) Infection
- 19 June 2020
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 11, 730
Open AccessActivation of Ang-(1-7)/Mas Receptor Is a Possible Strategy to Treat Coronavirus (SARS-CoV-2) Infection
Activation of Ang-(1-7)/Mas Receptor Is a Possible Strategy to Treat Coronavirus (SARS-CoV-2) Infection
- 1 May 2020
- Published by Elsevier in Immunobiology
- Vol. 225 (3) , 151957
Treatment with inhaled formulation of angiotensin-(1-7) reverses inflammation and pulmonary remodeling in a model of chronic asthma
- 1 May 2020
- Published by Elsevier in Immunobiology
- Vol. 225 (3) , 151957
Treatment with inhaled formulation of angiotensin-(1-7) reverses inflammation and pulmonary remodeling in a model of chronic asthma
- 1 March 2020
- Published by Elsevier in Immunobiology
- Vol. 225 (2) , 151893
Oral formulation angiotensin-(1-7) therapy attenuates pulmonary and systemic damage in mice with emphysema induced by elastase
- 1 March 2020
- Published by Elsevier in Immunobiology
- Vol. 225 (2) , 151893
Oral formulation angiotensin-(1-7) therapy attenuates pulmonary and systemic damage in mice with emphysema induced by elastase
- 16 December 2019
- Published by Springer Nature in Pediatric Nephrology
- Vol. 35 (5) , 815-827
Augmentation index, a predictor of cardiovascular events, is increased in children and adolescents with primary nephrotic syndrome
Arterial stiffness is associated with an increased risk of cardiovascular diseases. Augmentation index (AIx@75), a measure of arterial stiffness and wave reflection, has not been evaluated in patients with primary nephrotic syndrome (PNS). We investigated whether central and peripheral vascular profiles, hemodynamic parameters, and biochemical tests are associated with AIx@75 in PNS patients.
- 16 December 2019
- Published by Springer Nature in Pediatric Nephrology
- Vol. 35 (5) , 815-827
Augmentation index, a predictor of cardiovascular events, is increased in children and adolescents with primary nephrotic syndrome
Arterial stiffness is associated with an increased risk of cardiovascular diseases. Augmentation index (AIx@75), a measure of arterial stiffness and wave reflection, has not been evaluated in patients with primary nephrotic syndrome (PNS). We investigated whether central and peripheral vascular profiles, hemodynamic parameters, and biochemical tests are associated with AIx@75 in PNS patients.
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA4366
Mas receptor antagonist inhibits the pro-resolutive effects of Angiotensin-(1-7) in an experimental model of asthma
Introduction: Angiotensin-(1-7) [Ang- (1-7)] activates events that are crucial for the resolution of the inflammatory process of asthma. Objective: Investigate whether the blockade of the Mas receptor could alter the resolution of allergic lung inflammation. Methods: Balb/c mice were submitted to the experimental model of asthma. Sensitization was made by two injections of ovalbumin (OVA) in 2% aluminum hydroxide gel adjuvant at 7 days interval. On the 12th day, sensitized mice received OVA challenge until the 19th day. Mice were treated with Ang-(1-7) (OVA+Ang-(1-7) group) and A779 (OVA+Ang-(1-7)+A779 group), Mas receptor antagonist, at the peak of the inflammatory process. Mice were killed by an anesthetic overdose, 48, 72 and 96 hours after the last challenge with OVA and bronchoalveolar lavage fluid (BALF) was done and next, lungs were collected. Histological and morphometric analysis were performed in the lungs and inflammatory cells were counted in the BALF. Results: Treatment with Ang-(1-7) reduced the accumulation of eosinophil in the lung, as well as pulmonary inflammation, reduced the deposition of mucus and extracellular matrix in the airways at all evaluated times. However, in the OVA group, the natural resolution was observed only in the time of 96 hours after the last challenge. The pro-resolutive effects of Ang- (1-7) were inhibited by A779 and the resolution of inflammation was not observed at the times evaluated. Conclusion: Treatment with Ang- (1-7) accelerates the resolution of inflammation and the return of pulmonary homeostasis and Mas receptor blockade slow down this process in mice submitted to the experimental model of asthma.
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA4366
Mas receptor antagonist inhibits the pro-resolutive effects of Angiotensin-(1-7) in an experimental model of asthma
Introduction: Angiotensin-(1-7) [Ang- (1-7)] activates events that are crucial for the resolution of the inflammatory process of asthma. Objective: Investigate whether the blockade of the Mas receptor could alter the resolution of allergic lung inflammation. Methods: Balb/c mice were submitted to the experimental model of asthma. Sensitization was made by two injections of ovalbumin (OVA) in 2% aluminum hydroxide gel adjuvant at 7 days interval. On the 12th day, sensitized mice received OVA challenge until the 19th day. Mice were treated with Ang-(1-7) (OVA+Ang-(1-7) group) and A779 (OVA+Ang-(1-7)+A779 group), Mas receptor antagonist, at the peak of the inflammatory process. Mice were killed by an anesthetic overdose, 48, 72 and 96 hours after the last challenge with OVA and bronchoalveolar lavage fluid (BALF) was done and next, lungs were collected. Histological and morphometric analysis were performed in the lungs and inflammatory cells were counted in the BALF. Results: Treatment with Ang-(1-7) reduced the accumulation of eosinophil in the lung, as well as pulmonary inflammation, reduced the deposition of mucus and extracellular matrix in the airways at all evaluated times. However, in the OVA group, the natural resolution was observed only in the time of 96 hours after the last challenge. The pro-resolutive effects of Ang- (1-7) were inhibited by A779 and the resolution of inflammation was not observed at the times evaluated. Conclusion: Treatment with Ang- (1-7) accelerates the resolution of inflammation and the return of pulmonary homeostasis and Mas receptor blockade slow down this process in mice submitted to the experimental model of asthma.
- 27 September 2018
- Published by Wiley in Pediatric Diabetes
- Vol. 20 (2) , 202-209
Changes in aortic pulse wave components, pulse pressure amplification, and hemodynamic parameters of children and adolescents with type 1 diabetes
Introduction Type 1 diabetes mellitus (DM1) presents important risk factors for cardiovascular events. Objective To compare the components of the aortic pulse wave (APW) and the hemodynamic parameters among children and adolescents with DM1 and healthy individuals. Methods This is a cross‐sectional study, with 36 children and adolescents diagnosed with DM1 (11.9±3.2 years) matched by sex and age with the control group (n=36, 12.4±2.9 years). The components of the APW and the hemodynamic parameters were evaluated non‐invasively, using Mobil‐O‐Graph®. Results On the week of the evaluation, DM1 patients presented glycated hemoglobin (HbA1c) of 9.48±2.22% and fasting glycemia of 222.58±93.22 mg/dl. Augmentation index (AIx@75), reflection coefficient and augmentation pressure were significantly higher in DM1 group (29.0±9.7%, 63.0±7.9 and 7.8±2.7 mmHg, respectively) compared to control group (20.6±7.9%, 53.4±9.1 and 4.9±2.1 mmHg, respectively). The systolic volume (52.6±11.9 and 60±12.4 ml) and the cardiac output (4.3±0.5 and 4.6±0.5 L/min) decreased in the DM1 group in relation to the control group. The pulse pressure amplification (PPA) was significantly lower in the DM1 group (1.4±0.15) compared to the control group (1.6±0.17). PPA correlated negatively with total vascular resistance (TVR), augmentation pressure (AP) and reflection coefficient, and positively with cardiac index in both groups. In DMI group, the AIx@75 correlated negatively with age, height, systolic volume and PPA, and correlated positively with the TVR and reflection coefficient. Conclusion These results confirm the presence of arterial stiffness in this population and extend the knowledge, showing, for the first time, the reduction of PPA in the DM1 group.
- 27 September 2018
- Published by Wiley in Pediatric Diabetes
- Vol. 20 (2) , 202-209
Changes in aortic pulse wave components, pulse pressure amplification, and hemodynamic parameters of children and adolescents with type 1 diabetes
Introduction Type 1 diabetes mellitus (DM1) presents important risk factors for cardiovascular events. Objective To compare the components of the aortic pulse wave (APW) and the hemodynamic parameters among children and adolescents with DM1 and healthy individuals. Methods This is a cross‐sectional study, with 36 children and adolescents diagnosed with DM1 (11.9±3.2 years) matched by sex and age with the control group (n=36, 12.4±2.9 years). The components of the APW and the hemodynamic parameters were evaluated non‐invasively, using Mobil‐O‐Graph®. Results On the week of the evaluation, DM1 patients presented glycated hemoglobin (HbA1c) of 9.48±2.22% and fasting glycemia of 222.58±93.22 mg/dl. Augmentation index (AIx@75), reflection coefficient and augmentation pressure were significantly higher in DM1 group (29.0±9.7%, 63.0±7.9 and 7.8±2.7 mmHg, respectively) compared to control group (20.6±7.9%, 53.4±9.1 and 4.9±2.1 mmHg, respectively). The systolic volume (52.6±11.9 and 60±12.4 ml) and the cardiac output (4.3±0.5 and 4.6±0.5 L/min) decreased in the DM1 group in relation to the control group. The pulse pressure amplification (PPA) was significantly lower in the DM1 group (1.4±0.15) compared to the control group (1.6±0.17). PPA correlated negatively with total vascular resistance (TVR), augmentation pressure (AP) and reflection coefficient, and positively with cardiac index in both groups. In DMI group, the AIx@75 correlated negatively with age, height, systolic volume and PPA, and correlated positively with the TVR and reflection coefficient. Conclusion These results confirm the presence of arterial stiffness in this population and extend the knowledge, showing, for the first time, the reduction of PPA in the DM1 group.